Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yu, Chen ^a   Niu, Xiaogang ^a,b   Jin, Fan ^b   Liu, Zhirong ^a,b   Jin, Changwen ^a,b   Lai, Luhua ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; INTRINSICALLY DISORDERED PROTEIN; MYC PROTEIN; PROTEIN BINDING;

ANTAGONISTS AND INHIBITORS; CELL FREE SYSTEM; CHEMISTRY; COMPUTER INTERFACE; DRUG DESIGN; HL-60 CELL LINE; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRECLINICAL STUDY; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL-FREE SYSTEM; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HL-60 CELLS; HUMANS; INTRINSICALLY DISORDERED PROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN DOMAINS; PROTO-ONCOGENE PROTEINS C-MYC; STRUCTURE-ACTIVITY RELATIONSHIP; USER-COMPUTER INTERFACE;

EID: 84960153293     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22298     Document Type: Article

References (57)

1. Wright, P. E. & Dyson, H. J. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 293, 321-331 (1999).
2. Dunker, A. K. et al. The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics 9, S1 (2008).
3. Uversky, V. N. Intrinsically disordered proteins from A to Z. Int. J. Biochem. Cell Biol. 43, 1090-1103 (2011).
4. Schlessinger, A. et al. Protein disorder-a breakthrough invention of evolution? Curr. Opin. Struct. Biol. 21, 412-418 (2011).
5. Huang, Y. & Liu, Z. Kinetic advantage of intrinsically disordered proteins in coupled folding-binding process: a critical assessment of the "fly-casting" mechanism. J. Mol. Biol. 393, 1143-1159 (2009).
6. Dyson, H. J. & Wright, P. E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6, 197-208 (2005).
7. Ferreon, A. C., Ferreon, J. C., Wright, P. E. & Deniz, A. A. Modulation of allostery by protein intrinsic disorder. Nature 498, 390-394 (2013).
8. Liu, Z. & Huang, Y. Advantages of proteins being disordered. Protein Sci. 23, 539-550 (2014).
9. Metallo, S. J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 14, 481-488 (2010).
10. Cheng, Y. et al. Rational drug design via intrinsically disordered protein. Trends Biotechnol. 24, 435-442 (2006).
11. Uversky, V. N. Intrinsically disordered proteins and novel strategies for drug discovery. Expert Opin. Drug. Discov. 7, 475-488 (2012).
12. Wang, J., Cao, Z., Zhao, L. & Li, S. Novel strategies for drug discovery based on Intrinsically Disordered Proteins (IDPs). Int. J. Mol. Sci. 12, 3205-3219 (2011).
13. Zhu, M. et al. Identification of small-molecule binding pockets in the soluble monomeric form of the Abeta42 peptide. J. Chem. Phys. 139, 035101 (2013).
14. Toth, G. et al. Targeting the intrinsically disordered structural ensemble of alpha-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS One 9, e87133 (2014).
15. Yin, X., Giap, C., Lazo, J. S. & Prochownik, E. V. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22, 6151-6159 (2003).
16. Follis, A. V., Hammoudeh, D. I., Wang, H., Prochownik, E. V. & Metallo, S. J. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem. Biol. 15, 1149-1155 (2008).
17. Hammoudeh, D. I., Follis, A. V., Prochownik, E. V. & Metallo, S. J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc. 131, 7390-7401 (2009).
18. Harvey, S. R. et al. Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. J. Am. Chem. Soc. 134, 19384-19392 (2012).
19. Pei, J., Yin, N., Ma, X. & Lai, L. Systems biology brings new dimensions for structure-based drug design. J. Am. Chem. Soc. 136, 11556-11565 (2014).
20. Chen, C. Y. & Tou, W. I. How to design a drug for the disordered proteins? Drug Discov. Today 18, 910-915 (2013).
21. Meszaros, B., Simon, I. & Dosztanyi, Z. The expanding view of protein-protein interactions: complexes involving intrinsically disordered proteins. Phys. Biol. 8, 035003 (2011).
22. Prochownik, E. V. c-Myc as a therapeutic target in cancer. Expert Rev. Anticancer Ther. 4, 289-302 (2004).
23. Pelengaris, S., Khan, M. & Evan, G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2, 764-776 (2002).
24. Clausen, D. M. et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel smallmolecule inhibitor of c-Myc/Max dimerization. J. Pharmacol. Exp. Ther. 335, 715-727 (2010).
25. Cuchillo, R. & Michel, J. Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem. Soc. Trans. 40, 1004-1008 (2012).
26. Dunker, A. K. & Uversky, V. N. Drugs for 'protein clouds': targeting intrinsically disordered transcription factors. Curr. Opin. Pharmacol. 10, 782-788 (2010).
27. Smith, M. J., Charron-Prochownik, D. C. & Prochownik, E. V. The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation. Mol. Cell Biol. 10, 5333-5339 (1990).
28. Zhang, Y., Cao, H. & Liu, Z. Binding cavities and druggability of intrinsically disordered proteins. Protein Sci. 24, 688-705 (2015).
29. Jin, F., Yu, C., Lai, L. & Liu, Z. Ligand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteins. PLoS Comput. Biol. 9, e1003249 (2013).
30. Yuan, Y., Pei, J. & Lai, L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Curr. Pharm. Des. 19, 2326-2333 (2013).
31. Berg, T. et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl Acad. Sci. USA 99, 3830-3835 (2002).
32. Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749 (2004).
33. Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750-1759 (2004).
34. Dixon, S. et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des. 20, 647-671 (2006).
35. Huang, M.-J., Cheng, Y.-c., Liu, C.-R., Lin, S. & Liu, H. E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp. Hematol. 34, 1480-1489 (2006).
36. Wang, H. et al. Improved low molecular weight Myc-Max inhibitors. Mol. Cancer Ther. 6, 2399-2408 (2007).
37. Guo, J. et al. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother. Pharmacol. 63, 615-625 (2009).
38. Mustata, G. et al. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J. Med. Chem. 52, 1247-1250 (2009).
39. Jeong, K.-C., Ahn, K.-O. & Yang, C.-H. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest. Mol. Biosyst. 6, 1503-1509 (2010).
40. Wang, H. et al. Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. Oncotarget 4, 936-947 (2013).
41. Chauhan, J. et al. Discovery of methyl 4′-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1′-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization. ChemMedChem 9, 2274-2285 (2014).
42. Mayer, M. & Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 123, 6108-6117 (2001).
43. Meyer, B. & Peters, T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Ed. 42, 864-890 (2003).
44. Baell, J. B. & Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010).
45. Boldt, G. E., Eubanks, L. M. & Janda, K. D. Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem. Commun., 3063-3065 (2006).
46. Willems, H. & Gordon, R. inventors; De Novo Pharmaceuticals Ltd., assignee. Protected amino acid derivatives for the treatment of Alzheimer's disease. United Kingdom patent UK 2,392,443. 2004 Mar 3.
47. Yap, J. L. et al. Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorg. Med. Chem. Lett. 23, 370-374 (2013).
48. Kiessling, A., Sperl, B., Hollis, A., Eick, D. & Berg, T. Selective Inhibition of c-Myc/Max Dimerization and DNA Binding by Small Molecules. Chem. Biol. 13, 745-751 (2006).
49. Kiessling, A., Wiesinger, R., Sperl, B. & Berg, T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem 2, 627-630 (2007).
50. Stellas, D. et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J. Natl Cancer Inst. 106 (2014).
51. Hart, J. R. et al. Inhibitor of MYC identified in a Krohnke pyridine library. Proc. Natl Acad. Sci. USA 111, 12556-12561 (2014).
52. Muller, I. et al. Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors. PLoS One 9, e97285 (2014).
53. Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687-696 (2005).
54. Pearlman, D. A. et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 91, 1-41 (1995).
55. Case, D. et al. AMBER 12. University of California, San Francisco, CA. USA. URL http://ambermd.org/ (2012).
56. Horn, H. W. et al. Development of an improved four-site water model for biomolecular simulations: TIP4P-Ew. J. Chem. Phys. 120, 9665-9678 (2004).
57. Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 14, 33-38 (1996).